Journey Medical Expands Emrosi Access to Over 150 Million Commercial Lives
Journey Medical secured a contract with a third major GPO, expanding Emrosi payer access from approximately 100 million to over 150 million commercial lives as of April 1, 2026. This milestone raises U.S. commercial coverage to about 85%, positioning the brand for increased prescription demand and improved profitability.
1. Third GPO Contract Secured
Journey Medical finalized a contract with its third major group purchasing organization, enabling Emrosi access for an additional segment of commercial lives. This deal increases total payer access from around 100 million to over 150 million covered lives in the U.S. as of April 1, 2026.
2. Commercial Coverage Milestone
With approximately 85% of all U.S. commercial lives now able to access Emrosi, the company expects a significant uptick in prescription demand. Expanded coverage is key to converting payer access into plan formulary adoption, reducing reliance on co-pay assistance programs and enhancing margins.
3. Growth and Profitability Outlook
Management expects continued formulary adoption at both national and regional levels throughout 2026, positioning Emrosi for sustained commercial growth. Improved payer coverage and reduced discounting are projected to drive long-term value creation and profitability for the brand.